Most patients survive common thyroid cancer regardless of treatment
May 16, 2010 by admin · Leave a Comment
Contact: David Corriveau
David.A.Corriveau@Dartmouth.edu
603-653-0771
JAMA and Archives Journals
Individuals with papillary thyroid cancer that has not spread beyond the thyroid gland appear to have favorable outcomes regardless of whether they receive treatment within the first year after diagnosis, according to a report in the May issue of Archives of OtolaryngologyHead & Neck Surgery, one of the JAMA/Archives journals.
Breakthrough in Thyroid Cancer May Enable More Targeted Risk Assessment and Earlier Intervention
February 6, 2009 by admin · Leave a Comment
Scientists at deCODE genetics (Nasdaq: DCGN) today present the discovery of two single letter variations in the sequence of the human genome (SNPs) conferring substantial increased risk of thyroid cancer. The two SNPs, located on chromosomes 9q22 and 14q13, are the first common variants replicated in multiple populations ever associated with increased risk of the disease. They were found through the analysis of the genomes of a total of more than 40,000 patients and control subjects from Iceland, the United States and Spain. Approximately 4 percent of people of European descent carry two copies of the at-risk versions of both SNPs, putting them at a 5.7-times greater risk of thyroid cancer than individuals who carry no copies of either. These variants contribute to an estimated 57 percent of all cases of the disease, and they associate with altered levels of key thyroid hormones.
Early trial of new multi-kinase inhibitor shows impressive activity in thyroid cancer
October 23, 2008 by admin · Leave a Comment
Preliminary trials of a new multi-kinase inhibitor have indicated it has impressive tumour shrinkage activity in patients with a difficult to treat type of thyroid cancer. The results have put the drug’s development on a fast track, prompting the accelerated initiation of a large phase III trial.
Early detection critical in treating pediatric thyroid cancer
February 1, 2008 by admin · Leave a Comment
Efforts to treat pediatric papillary thyroid cancer are greatly improved by detecting the disease as early as possible, making the patient’s age the most important factor in determining a prognosis, according to new research published in the February 2008 issue of the journal Otolaryngology – Head and Neck Surgery.
Experimental drug shows promise in advanced kidney cancer
September 26, 2007 by admin · Leave a Comment
Barcelona, Spain: A new drug has shown promise in patients with advanced kidney cancer whose options run out after their tumour fails to respond to the cutting edge therapy.
The study, presented today (Wednesday) at the European Cancer Conference (ECCO 14) in Barcelona, showed that the experimental drug, axitinib, shrank tumours and delayed progression of the disease in a group of patients who are among the toughest to treat.
Survivor Spotlight: Renee, living life to the fullest
May 25, 2007 by admin · Leave a Comment
Filed under: Thyroid Cancer, Survivor Spotlight
Thyroid cancer discovery points to new treatments, prevention
November 28, 2006 by admin · Leave a Comment
Molecular mechanisms of cancer-causing protein revealed
KINGSTON, Ont. — The actions of a mutated protein in cells linked to thyroid cancer have been uncovered by researchers at Queen’s University. The discovery paves the way for the future development of drugs to more effectively target, treat and possibly even prevent both inherited and non-inherited thyroid cancers.
